Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhamnus extract is a botanical preparation derived from plants of the genus *Rhamnus*, commonly known as buckthorns. These extracts, often prepared using solvents like methanol for research purposes, contain a variety of secondary metabolites, most notably anthraquinones such as emodin, frangulin, and cascarosides. While traditionally used as stimulant laxatives (e.g., Cascara sagrada), *Rhamnus* extracts are being explored for potential antineoplastic activity. Research presented at the AACR 2017 Annual Meeting indicated that methanolic extracts of *Rhamnus* exhibit inhibitory effects on the viability of several cancer cell lines, including lung (A549), colon (SW620 and Colo320), breast (BT549), and cervical (HeLa) cancers. The specific molecular mechanisms and clinical efficacy in oncology remain to be established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhamnus extract.